Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy

Khon Kaen University

Status and phase

Completed

Phase 4

Conditions

Proliferative Diabetic Retinopathy

Vitreous Hemorrhage

Treatments

Drug: intravitreal injection of bevacizumab

Study type

Interventional

Funder types

Other

Identifiers

NCT01724385

I55116

Details and patient eligibility

About

To evaluate the efficacy of intravitreal bevacizumab injections for treatment of proliferative diabetic retinopathy (PDR) with new dense vitreous hemorrhage (VH) after previous full panretinal photocoagulation (PRP).

Full description

The investigators will carry out a prospective study in patients with PDR and prior complete laser treatment who presented with new dense VH. All eyes will be treated with intravitreal injection of bevacizumab (1.25 mg). Complete ophthalmic examination and/or ocular ultrasonography will be performed at baseline and 1, 6, 12 weeks and 6, 9, 12 months after first injection. Re-injection will be done in non-clearing and recurrent VH.

Enrollment

18 patients

Sex

All

Ages

20 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

patients with diabetes mellitus
proliferative diabetic retinopathy
prior complete panretinal photocoagulation
presented with new dense vitreous hemorrhage

Exclusion criteria

one-eyed patient
previous intraocular surgery
severe lens opacity precluding fundus examination
advance glaucoma
history of thromboembolic events such as myocardial infarction and cerebrovascular accident
uncontrolled systemic hypertension, systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg
known coagulation abnormalities or current use of anticoagulant medications other than aspirin
known allergies to any relevant drugs in this study
evidence of external ocular infection such as conjunctivitis and significant blepharitis.